The cumulative incidence of grade 2-4 acute graft-versus-host disease was 46 % ( 95 % CI 32-62 ) in the rituximab group and 42 % ( 95 % CI 29-59 ) in the no rituximab group ( hazard ratio [ HR ] 091 , 95 % CI 052-160 ; p = 074 ) .